ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced its AgriFood innovation and investment platform, ICL Planet Startup Hub, has invested €2.75 million in Arkeon, GmbH. The investment will support Arkeon’s innovative and sustainable one-step fermentation bioprocess, which creates completely customizable protein ingredients by capturing the greenhouse gas carbon dioxide (CO2) and converting it into the 20 proteinogenic amino acids necessary for human nutrition. The resulting alternative proteins are carbon negative and clean-label functional ingredients.
Arkeon’s patented process pioneered the harnessing of carbon dioxide to make protein – through the use of archaea, a highly resilient single-celled microorganism – without genetic engineering. Archaea, part of the microbiota of all organisms, naturally feeds on CO2 and transforms these environmental emissions into nutritious protein – meaning the process is not just sustainable, it is also regenerative.
“I dedicated much of the past decade to exploring new and sustainable biotechnological methods of alternative protein production,” said Gregor Tegl, PhD, co-founder and CEO of Arkeon. “Our team has harnessed proficiencies in microbiology and gas fermentation to create an entirely new regenerative food-production system. ICL’s support and partnership will be instrumental in helping us scale our archaea-derived protein production capabilities.”
“Arkeon has achieved a major breakthrough, by finding a way to nourish people and revitalize our ecosystems at the same time,” said Hadar Sutovsky, vice president of External Innovation at ICL, and general manager of ICL Planet. “Arkeon’s dedication to developing a renewable and easy to use protein is completely in-line with our organization’s commitment to creating impactful solutions for humanity’s sustainability challenges in the global food markets.”
“Although a young company, Arkeon brings to the table innovative and sustainable technology for use in creating the next generation of alternative protein products. They also fully align with ICL Food Specialties growth strategy of pursuing new frontiers in unique and functional alternative proteins,” added Rado Sporka, vice president of the Food Specialties Commercial Business for ICL. “As an established corporation, we are able to offer our advanced infrastructure, extensive experience and accrued insights, plus market and regulatory related support. We look forward to working with this promising start-up to unlock a whole new food category based on Arkeon’s unique protein discovery, which is not dependent on land and requires minimal use of water, providing it with a limited ecological footprint.”
ICL is leading the current SAFE investment round, which totals more than €4 million and includes other investors, as well. As the newest portfolio member of ICL’s Planet Startup Hub, Arkeon will have full access to the ICL Food Specialties state-of-the-art R&D labs and production facilities. Arkeon marks ICL’s third investment over the past 12 months, via its Planet Startup Hub, which the company launched in 2021. The accelerator was established to nurture and advance both early stage and pilot-ready innovative companies operating within the FoodTech and AgriTech domains.
ICL Group Ltd. is a leading global specialty minerals company, which creates impactful solutions for humanity’s sustainability challenges in the food, agriculture and industrial markets. ICL leverages its unique bromine, potash and phosphate resources, its global professional workforce, and its sustainability focused R&D and technological innovation capabilities, to drive the company’s growth across its end markets. ICL shares are dual listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL). The company employs more than 12,500 people worldwide, and its 2021 revenues totaled approximately $7 billion.
For more information, visit ICL’s website at www.icl-group.com.
About Arkeon GmbH (Arkeon)
Arkeon is an ingredients company, based in Vienna, Austria, leveraging the power of ancient microbes to convert CO2 directly into protein ingredients. The company’s proprietary technology is a new, innovative approach to produce amino acids and functional peptides for food and lifestyle products, enabling a regenerative way to nourish people on a global scale. The company’s technological foundations have been built up over a decade of research by Co-Founders Dr. Simon Rittmann, Dr. Guenther Bochmann, and Dr. Gregor Tegl.
For more information, visit www.arkeon.bio.
Forward Looking Statements
This announcement contains statements that constitute forward looking statements, many of which can be identified by the use of forward looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others.
Forward-looking statements appear in this press release and include, but are not limited to, statements regarding the company’s intent, belief or current expectations. Forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: estimates, forecasts and statements as to management’s expectations with respect to, among other things, business and financial prospects, financial multiples and accretion estimates, future trends, plans, strategies, positioning, objectives and expectations, general economic, market and business conditions, supply chain and logistics disruptions, energy storage and electric vehicle growth, the potential for new COVID-19 variants, global unrest and conflict, governmental and regulatory requirements and actions by governmental authorities, including changes in government policy, changes in environmental, tax and other laws or regulations and the interpretation thereof. As a result of the foregoing, readers should not place undue reliance on the forward‐looking statements contained in this press release concerning the timing of the transaction, or other more specific risks and uncertainties facing ICL, such as those set forth in the “Risk Factors” section of its Annual Report on Form 20-F filed on February 23, 2022, as such risk factors may be updated from time to time in its Current Reports on Form 6-K and other filings ICL makes with the U.S. Securities and Exchange Commission from time to time.
Forward-looking statements refer only to the date they are made, and the company does not undertake any obligation to update them in light of new information or future developments or to publicly release any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.